PRehabilitiation in Elective Frail and Elderly Cardiac Surgery PaTients (PREFECT)

June 17, 2019 updated by: Ottawa Heart Institute Research Corporation

PRehabilitiation in Elective Frail and Elderly Cardiac Surgery PaTients (PREFECT): Assessing the Impact of a Personalized Prehabilitation Program Before Cardiac Surgery on Frailty and Clinical Outcomes

Older and more frail adults are more often being referred for cardiac surgery. These patients are often in suboptimal health, and may be physically frail, malnourished, and have other conditions, such as diabetes, that complicate their recovery. Research suggests that a rehabilitation program prior to surgery may help improve participants' health and improve their fitness for surgery. Currently, a pre-operative rehabilitation workshop is offered at the University of Ottawa Heart Institute, but this interventional, randomized study will investigate whether a more comprehensive pre-operative regime, including structured weekly exercise program, is more effective at improving health prior to surgery. Patients will be randomized to either the control group (pre-operative rehabilitation workshop ONLY) or the treatment group (pre-operative rehabilitation workshop plus exercise regime). This regime will attempt to improve patients' overall health, including their physical fitness and nutritional status. The effectiveness of this regime will be evaluated by comparing patients' physical function, questionnaires (diet, quality of life, stress) and serum biomarkers from baseline to pre-surgery to post-surgery. The Investigators hypothesize that patients that complete the pre-operative rehabilitation program will improve their health prior to surgery, and that this may result in shorter length of hospitalization and fewer complications after surgery. The study will take place over two years, with each patient's participation lasting about 3 months.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Withdrawn

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Frailty is a common syndrome among older adults, defined as a "clinically recognizable state of increased vulnerability resulting from aging-associated decline in reserve and function". Fried defined frailty as meeting three out of the five criteria: low grip strength, low energy, slowed walking speed, low physical activity, and/or unintentional weight loss. Clinicians are currently challenged with a rising prevalence of elderly and frail patients presenting for major cardiac surgery. Such patients typically present with a greater comorbidity burden and are more likely to be malnourished, physically deconditioned, and to exhibit decreased physiological adaptation to stress. Frail cardiac surgical patients are, unsurprisingly, at increased risk for major adverse cardiac and cerebrovascular events, short- and longer-term mortality, and increased length of hospital of stay. Clinicians may also struggle to quantify the peri-operative risk of morbidity and mortality among these individuals, since tools such as the Society of Thoracic Surgeons (STS) risk assessment are not designed to comprehensively assess the complex interaction between various risk factors seen in the frail patient.

Cardiovascular rehabilitation (CR) programs are integral to managing patients with cardiovascular disease. Such programs include health behaviour change, and cardiovascular risk factor management (e.g. moderate-to-vigorous-intensity continuous exercise training [MICE], healthy eating, smoking cessation, stress management, and psychological services). The benefits of MICE for patients with cardiovascular disease include improvements in exercise tolerance, muscular strength, cardiovascular health and reduced hospitalizations. MICE is, therefore, able to improve several facets of physical dysfunction, and forms major therapeutic interventions for functional capacity and frailty. Improvements in nutritional status have been observed in patients with cardiovascular disease(CVD) participating in CR, and exercise training and stress management have been shown to reduce distress in CVD patients.

Emerging evidence indicates that CR before cardiac surgery (i.e. prehabilitation [PREHAB]) may improve clinical outcomes. Sawatzky et al. showed that a 12-week PREHAB program consisting of two structured exercise training sessions per week and 12 education sessions concerning cardiovascular risk factor management, exercise, stress, diet, and medication use in patients awaiting coronary artery bypass grafting (CABG) was feasible and significantly improved functional capacity.

Elderly and frail patients are increasingly presenting for cardiac surgery, and these individuals must be carefully optimized pre-operatively to increase the likelihood of their recovery and return to a reasonable quality of life. A personalized PREHAB program that targets and ameliorates the elements of frailty, including low functional capacity, poor nutrition, and stress, offers the best chance of mitigating frailty and its associated risk factors in a way that is feasible, patient-centred, and translatable to other cardiovascular centres. This project will use objective measures, including tests of functional capacity, validated questionnaires, and biomarker analysis, to better quantify the subjective diagnosis of frailty in our patients, and will implement a novel personalized PREHAB program with integrated on-site and home-based exercise sessions, in an attempt to mitigate the frailty and other risk factors that impact patients in the peri-operative period.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Ottawa, Ontario, Canada, K1Y4W7
        • University of Ottawa Heart Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients >18 years of age
  • Patients able to provide informed consent
  • Patients undergoing elective cardiac surgery for either CABG, valve, or CABG + valve
  • Patients who have an estimated wait time of at least 10 weeks.
  • Patients who are either ≥65 years of age or classified as frail using Fried Frailty criteria or scoring at least 3 on the Clinical Frailty Scale

Exclusion Criteria:

  • Patients with current or recent unstable cardiac disease, defined as and of the following:
  • CCS class IV angina,
  • NYHA Class III or IV heart failure,
  • Critical left main disease,
  • hospitalization for arrhythmia within the last month
  • Dynamic ventricular outflow obstruction
  • Symptomatic exercise-induced arrhythmia
  • Patients who are cognitively, geographically or physically unable to complete the PREHAB sessions
  • Patients who, in the opinion of either their treating physician or the study investigators, should not participate in a pre-operative rehabilitation program.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: PREHAB Group

Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.

Patients in this group will also complete an 8-week PREHAB exercise program, with weekly exercise classes and a list of exercises to complete at home.
Behavioral: PREHAB Workshop
PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
Behavioral: PREHAB Exercise Program
An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
Active Comparator: Standard of care group
Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
Behavioral: PREHAB Workshop
PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Functional capacity
Time Frame: Change between baseline and 8 weeks (+/- 1 week)
The primary outcome, functional capacity, will be measured using the 6-minute walk test.
Change between baseline and 8 weeks (+/- 1 week)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Frailty (Fried criteria)
Time Frame: Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Measured using the Fried frailty score (presence of 3 of the 5 symptoms of frailty)
Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Frailty (clinical score)
Time Frame: Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Measured using the Clinical Frailty Scale (9 point clinical assessment)
Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Short Form - 36
Time Frame: Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Measured using the SF-36 Quality of Life questionnaire
Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Depression
Time Frame: Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Measured using the BDI-II
Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Anxiety
Time Frame: Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Measured using the BAI
Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Dietary habits
Time Frame: Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Measured using the Block food frequency questionnaire
Compared between baseline, 8 weeks (+/- 1 week), and 4 weeks after surgery (+/- 2 weeks)
Exercise adherence
Time Frame: Compared between baseline and 8 weeks (+/- 1 week)
Measured using a pedometer
Compared between baseline and 8 weeks (+/- 1 week)
Clinical and cardiovascular outcomes
Time Frame: In the 6 weeks after surgery
A composite endpoint that will look at the rates of occurrence of major cardiovascular and cerebrovascular outcomes (i.e. death, myocardial infarction, cardiac arrest, stroke) and length of hospitalization.
In the 6 weeks after surgery

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Biomarkers
Time Frame: Compared between baseline and 8 weeks (+/- 1 week)
An exploratory outcome where we will examine a panel of biomarkers to determine the biomarker profile of frail and elderly patients referred for cardiac surgery, and to observe what changes, if any, occur after the PREHAB intervention. The biomarker panel includes markers of cardiovascular health and risk (NT-pro BNP, cholesterol, homocysteine), nutritional status (albumin, prealbumin, trasnferrin receptor, 25-hydroxy-vitamin D), inflammation (interleukin 6, selenium, high sensitivity CRP, sRAGE), renal function (creatinine, cystatin C), liver function (AST, ALT), and overall health (CBC, adiponectin, dehydroepiandrosterone sulfate, sex hormone-binding globulin, insulin-like growth factor).
Compared between baseline and 8 weeks (+/- 1 week)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ottawa Heart Institute Research Corporation

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Juan B Grau Alvaro, MD, Ottawa Heart Institute Research Corporation
  • Principal Investigator: Louise Sun, MD, Ottawa Heart Institute Research Corporation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 20, 2018

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2019

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 20, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 11, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 16, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 20, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 17, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 20170698

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on PREHAB Workshop

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings